Keyphrases
Moderate to Severe
100%
Monotherapy
100%
Thyroid-stimulating Immunoglobulin
100%
Methylprednisolone
100%
Thyroid Eye Disease
100%
Second-line Treatment
44%
Mycophenolate Mofetil
33%
Immunoglobulin Levels
22%
Clinical Activity Score
22%
No Response
11%
Best Response
11%
Treatment Initiation
11%
Late Relapse
11%
Partial Response
11%
Tocilizumab
11%
Rituximab
11%
Treatment Completion
11%
Early Relapse
11%
Close Monitoring
11%
Second Course
11%
Dual Therapy
11%
Methylprednisolone Pulse Therapy
11%
EUGOGO
11%
Medicine and Dentistry
Monotherapy
100%
Thyroid Stimulating Immunoglobulin
100%
Methylprednisolone
100%
Endocrine Ophthalmopathy
100%
Mycophenolate Mofetil
33%
Intravenous Drug Administration
11%
Rituximab
11%
Tocilizumab
11%
Pharmacology, Toxicology and Pharmaceutical Science
Monotherapy
100%
Thyroid Stimulating Immunoglobulin
100%
Methylprednisolone
100%
Endocrine Ophthalmopathy
100%
Mycophenolate Mofetil
33%
Intravenous Therapy
11%
Tocilizumab
11%
Rituximab
11%
Immunology and Microbiology
Methylprednisolone
100%
Graves' Ophthalmopathy
100%
Thyroid Stimulating Immunoglobulin
100%
Mycophenolate Mofetil
33%
Immunoglobulin Blood Level
22%
Rituximab
11%
Tocilizumab
11%
Neuroscience
Thyroid Stimulating Immunoglobulin
100%
Methylprednisolone
100%
Thyroid Eye Disease
100%
Mycophenolate Mofetil
33%
Rituximab
11%
Tocilizumab
11%